Every Form 4 that Pharmacyte Biotech Inc (PMCB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PMCB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMCB filings page.
WALKER WAYNE REMELL reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech, Inc. director Wayne Remell Walker reported an administrative correction to a prior stock option grant. The footnote explains that the grant was made in error and has been cancelled, leaving 0.0000 derivative securities from this grant and no common stock bought or sold.
Abecassis Michael M reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech, Inc. director Michael M. Abecassis reported an amended insider transaction dated 2026-03-31 involving a stock option classified as a derivative security.
The amendment states the previously reported grant was made in error and has been cancelled, with 0.0000 shares and 0.0000 derivative holdings shown after this correction.
SCHECHTER JONATHAN reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech director Jonathan Schechter filed an amended insider report for a stock option (right to buy) entry dated March 31, 2026. A footnote explains that the reported grant was made in error and has been cancelled, leaving 0 options from this grant outstanding.
WEINSTEIN ROBERT reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech, Inc. director Robert Weinstein reported a correction to a stock option award. A previously reported Stock Option (Right to Buy) grant dated 2026-03-31 was made in error and has been cancelled, leaving 0 derivative shares transacted and 0 shares remaining from that specific grant.
PharmaCyte Biotech, Inc. reported that director Robert Weinstein received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share, were awarded at no cost, and expire on March 30, 2036. They will vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.
PharmaCyte Biotech, Inc. director Wayne Remell Walker received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share and expire on March 30, 2036, with 119,170 derivative securities held after this grant.
According to the filing, the options will vest in full on the date of the company’s next annual meeting of stockholders, subject to Mr. Walker’s continued service. This award is characterized as a grant or other acquisition of derivative securities rather than an open-market purchase.
PharmaCyte Biotech director Jonathan Schechter received a grant of stock options for 119,170 shares of Common Stock. The options have a $0.67 exercise price, expire on March 30, 2036, and were awarded as compensation, not an open-market purchase. They vest in full at the issuer's next annual stockholder meeting, subject to his continued service, leaving him with 119,170 options following this grant.
PharmaCyte Biotech, Inc. director Michael M. Abecassis received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share and expire on March 30, 2036. According to the terms, the options vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.
PharmaCyte Biotech, Inc., identified as a ten percent owner of FEMASYS INC, filed a Form 4 related to FEMASYS common stock. The provided data show no reported purchases, sales, or derivative exercises, with all transaction counters and share amounts recorded as zero.
PharmaCyte Biotech, Inc. CEO and President Joshua Silverman reported multiple open-market purchases of the company’s common stock. On January 5, 2026, he bought 30,000 shares at $0.7831 per share. On January 6, 2026, he bought another 30,000 shares at $0.7889 per share, and on January 7, 2026, he bought 40,000 shares at $0.8329 per share.
After these transactions, Silverman directly beneficially owned 416,250 shares of PharmaCyte common stock and indirectly beneficially owned an additional 50,000 shares through JNS Holdings Group LLC.
PharmaCyte Biotech director buys additional shares
Director Jonathan Schechter reported buying a total of 60,000 shares of PharmaCyte Biotech, Inc. common stock in the open market over three consecutive days. He purchased 20,000 shares on January 5, 2026 at $0.7776 per share, 20,000 shares on January 6, 2026 at $0.7904 per share, and 20,000 shares on January 7, 2026 at $0.8436 per share. Following these transactions, Schechter directly owned 192,500 shares of PharmaCyte common stock.
PharmaCyte Biotech, Inc. reported equity award activity for director Wayne R. Walker. On 12/12/2025, 37,500 shares of common stock were acquired at $0 per share, and 16,875 shares were disposed of at $1.02 per share to satisfy tax liability upon vesting of restricted stock units, leaving 20,625 shares of common stock directly owned.
Walker also reported receiving 63,233 stock options on 04/25/2025 with an exercise price of $1.22 per share, expiring on 04/24/2035 and covering 63,233 shares of common stock. These options will vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service, and the company notes the transaction was reported late due to an inadvertent administrative error, not any error of Mr. Walker.
PharmaCyte Biotech, Inc. reported insider equity activity by CEO, President and Director Joshua N. Silverman on 12/12/2025. He acquired 575,000 shares of common stock at $0, increasing his direct holdings.
On the same day, 258,750 shares were disposed of at $1.02 to satisfy the tax liability upon vesting of restricted stock units, and this withholding did not involve an open-market sale. After these transactions, Silverman beneficially owned 316,250 shares directly and 50,000 shares indirectly through JNS Holdings Group LLC.
PharmaCyte Biotech director Jonathan Schechter reported recent equity compensation activity. On 12/12/2025, he acquired 150,000 shares of common stock, with 67,500 shares withheld to cover taxes related to vesting restricted stock units, so the withholding did not involve an open-market sale.
On 04/25/2025, he was also granted stock options covering 63,233 shares of common stock at an exercise price of $1.22 per share, expiring on 04/24/2035. These options are scheduled to vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.
PharmaCyte Biotech, Inc., as a reporting person and 10% owner of Q/C Technologies, Inc. (QCLS), reported derivative equity transactions on a Form 4. On 09/04/2025, the reporting person acquired 889,865 shares of Series H Convertible Preferred Stock and related warrants, each ultimately linked to 889,865 shares of common stock. The Series H preferred is convertible into common stock at a conversion price of $3.3713 per share, subject to adjustment, and its conversion rights do not expire. Both the Series H preferred and the warrants became convertible only after shareholders approved the issuance of the underlying common stock at a special meeting held on November 14, 2025, with the warrants expiring on November 14, 2030.